Inspire Medical Systems (INSP)
NYSE:INSP
INSP Stock Chart & Stats
$51.41
-$1.46(-0.68%)
At close: 4:00 PM EST
$51.41
-$1.46(-0.68%)
Day’s Range― - ―
52-Week Range$50.00 - $164.02
Previous CloseN/A
Volume95.34K
Average Volume (3M)1.29M
Market Cap
$1.47B
Enterprise Value$1.42B
Total Cash (Recent Filing)$308.27M
Total Debt (Recent Filing)$62.15M
Price to Earnings (P/E)4.9
Beta0.50
Next Earnings
May 05, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.65
Shares Outstanding28,589,290
10 Day Avg. Volume959,349
30 Day Avg. Volume1,292,024
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.56
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda20.39
Forecast
1Y Price Target
$77.10Price Target Upside49.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)1.93
Revenue Forecast (FY)$965.75M
Bulls Say, Bears Say
Bulls Say
Financial Performance And ValuationThe company demonstrated positive profitability and trades at a low revenue multiple, with a potential replacement cycle that could support further margin expansion and a valuation re‑rating.
Product Differentiation And Market PositionThe company sells a first‑in‑class, FDA‑approved hypoglossal nerve stimulation system for obstructive sleep apnea patients who failed positive airway pressure therapy, supporting differentiated clinical demand and referral momentum.
Reimbursement StabilityCMS mapped the new procedure codes to the same hospital payment category as the existing therapy, keeping hospital reimbursement for the Inspire V procedure consistent and reducing the risk of hospital payment disruption.
Bears Say
Coding And Payment HeadwindRecent coding and payment reversals removed a prior pricing tailwind and increase the risk of lower per‑procedure revenue, creating a headwind to near‑term revenue growth.
Physician Payment UncertaintyUnresolved physician reimbursement tied to a billing modifier creates uncertainty that can reduce doctor incentives and slow procedure uptake.
Regional Coverage FragmentationRemoval of an obstructive sleep apnea diagnosis for the relevant CPT code by some Medicare contractors, combined with no national coverage decision, produces inconsistent regional reimbursement that could delay new center activations.
Inspire Medical Systems News
INSP FAQ
What was Inspire Medical Systems’s price range in the past 12 months?
Inspire Medical Systems lowest stock price was $50.00 and its highest was $164.02 in the past 12 months.
What is Inspire Medical Systems’s market cap?
Inspire Medical Systems’s market cap is $1.47B.
When is Inspire Medical Systems’s upcoming earnings report date?
Inspire Medical Systems’s upcoming earnings report date is May 05, 2026 which is in 39 days.
How were Inspire Medical Systems’s earnings last quarter?
Inspire Medical Systems released its earnings results on Feb 11, 2026. The company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.742 by $0.908.
Is Inspire Medical Systems overvalued?
According to Wall Street analysts Inspire Medical Systems’s price is currently Undervalued.
Does Inspire Medical Systems pay dividends?
Inspire Medical Systems does not currently pay dividends.
What is Inspire Medical Systems’s EPS estimate?
Inspire Medical Systems’s EPS estimate is -0.32.
How many shares outstanding does Inspire Medical Systems have?
Inspire Medical Systems has 28,589,290 shares outstanding.
What happened to Inspire Medical Systems’s price movement after its last earnings report?
Inspire Medical Systems reported an EPS of $1.65 in its last earnings report, beating expectations of $0.742. Following the earnings report the stock price went down -12.549%.
Which hedge fund is a major shareholder of Inspire Medical Systems?
Currently, no hedge funds are holding shares in INSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$77.10 (49.97% Upside)
$77.10 (49.97% Upside)
Blogger Sentiment
Bullish
INSP Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 822.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.83%
12-Months-Change
Fundamentals
Return on Equity
21.07%
Trailing 12-Months
Asset Growth
13.62%
Trailing 12-Months
Company Description
Inspire Medical Systems
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
INSP Company Deck
INSP Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: strong 2025 financial results, cash generation, buybacks, and clear clinical and commercial traction for Inspire 5 (training, high center adoption, superior clinical metrics). However, material near-term reimbursement and coding uncertainty (transition to CPT 64582 with a -52 modifier), the WISER prior-authorization pilot, and inconsistent claims processing introduce significant short- to medium-term risk that widened 2026 guidance and could constrain physician willingness and early-year procedures. Management has a dual-path remediation plan (short-term payer engagement to reduce the modifier impact and long-term pursuit of a new CPT code), plus product and operational levers, but the timing and magnitude of reimbursement outcomes remain the key risk to achieving the higher end of guidance.View all INSP earnings summariesINSP Revenue Breakdown
97.02% U.S.
2.98% Other
INSP Stock 12 Month Forecast
Average Price Target
$77.10
▲(49.97% Upside)
Technical Analysis
Integer Holdings
―
LivaNova
―
Irhythm Technologies
―
TransMedics Group
―
PROCEPT BioRobotics
―
Ownership Overview
Currently, No data available
---